Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.
Principal Investigator:
Jeffrey Cohen | Cleveland Clinic | Cleveland, OH
Paolo Muraro | Imperial College London | London, England
George Georges | Fred Hutchinson Cancer Research Center | Chicago, IL
BEAT-MS is a clinical trial comparing chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) – a type of bone marrow transplantation – to the most effective medicines regularly used to treat relapsing MS.
Category:
Autoimmune Disease
|
Specific Category:
Multiple Sclerosis
|
Status:
Enrollment
Learn more:
(
ITN075AI
|
BRAVOS
)
Principal Investigator:
Dinesh Khanna | University of Michigan | Ann Arbor, MI
David Fox | University of Michigan | Ann Arbor, MI
BRAVOS is a clinical trial evaluating Brentuximab Vendotin treatment for Diffuse Cutaneous Systemic Sclerosis.
Category:
Autoimmune Disease
|
Specific Category:
Scleroderma
|
Status:
Analysis
Learn more:
(
ITN073ST
|
LITTMUS_MGH
)
Principal Investigator:
James Markmann | Massachusetts General Hospital | Philadelphia, PA
Eva Guinan | Boston, MA
LITTMUS is a clinical research study testing a new approach to achieve transplant tolerance using the liver transplant recipient’s own T regulatory cells (Tregs).
Category:
Transplantation
|
Specific Category:
Liver Transplantation
|
Status:
Follow-up
Learn more:
(
ITN070AD
|
LEAP Trio
)
Principal Investigator:
Gideon Lack | Kings College London | London, England
LEAP Trio is a follow-up to the LEAP study of early peanut consumption. LEAP Trio will investigate the durability of tolerance to peanut allergen in LEAP participants at age 12, development of peanut allergy in younger siblings of LEAP participants, and parental characteristics that may impact development of food allergy.
Category:
Allergy & Asthma
|
Specific Category:
Peanut Allergy
|
Status:
Analysis
Learn more:
(
ITN066AI
|
T1DES
)
Principal Investigator:
Linda DiMeglio | Indiana University and Riley Hospital for Children | Indianapolis, IN
Mark Rigby | Indiana University | Indianapolis, IN
T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study.
Category:
Type 1 Diabetes
|
Specific Category:
Type 1 Diabetes
|
Status:
Follow-up
Learn more:
(
ITN063ST
|
ALLTOL
)
Principal Investigator:
Sindhu Chandran | Immune Tolerance Network | San Francisco, CA
ALLTOL is a clinical study to learn more about tolerance in organ transplantation. This study is observational, meaning there are no study medications or procedures. This study will last for up to five years, and will require 1 study visit per year. These visits will include overall health assessment and blood and urine collections.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Complete
Learn more:
(
ITN062ST
|
TEACH
)
Principal Investigator:
Allan Kirk | Duke University School of Medicine | Durham, NC
TEACH is a clinical trial investigating whether cells from the kidney donor's bone marrow, called mesenchymal stromal cells (MSCs) will allow kidney transplant recipients to stop immunosuppressive medications.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Follow-up
Learn more:
(
ITN061AD
|
Cat EEC
)
Principal Investigator:
Stephen Durham | Imperial College London | London, England
Piyush Patel | | Mississauga, ON
The goal of the CAT EEC study is to directly compare allergic responses to cat by environmental exposure chamber vs. nasal allergen challenge to better understand and employ these methods as allergy evaluation tools in clinical trials.
Category:
Allergy & Asthma
|
Specific Category:
Cat Allergy
|
Status:
Complete
Learn more:
(
ITN059AI
|
PAUSE
)
Principal Investigator:
James Krueger | The Rockefeller University | New York, NY
PAUSE is a clinical trial testing the effectiveness of ustekinumab (STELARA ®) followed by an investigational drug, abatacept, for the treatment of psoriasis. The main goal of the study is to determine the efficacy of abatacept to induce prolonged remission.
Category:
Autoimmune Disease
|
Specific Category:
Psoriasis Vulgaris
|
Status:
Complete
Learn more:
(
ITN058AI
|
EXTEND
)
Principal Investigator:
Carla Greenbaum | Benaroya Research Institute | Seattle, WA
Jane Buckner | Benaroya Research Institute | Seattle, WA
EXTEND is a clinical research study that will test whether a therapy called tocilizumab (Actemra®) can stop the immune system from attacking the remaining beta cells and possibly extend the ability to naturally produce insulin in individuals recently diagnosed with type 1 diabetes.
Category:
Type 1 Diabetes
|
Specific Category:
Type 1 Diabetes
|
Status:
Complete
Learn more:
No items found.
